MNPR slides over 5% as technical signals forecast further downside risk

Traders Union
All News
Stocks
Monopar therapeutics slides 5.25% today

Highlights

Monopar Therapeutics will present new Phase 3 FoCus baseline data and ALXN1840 molybdenum safety results at The Liver Meeting 2026.
The company continues active clinical research in liver therapies, reporting progress in multiple trials.
Shares of Monopar Therapeutics closed at $66.97, trading with sustained bearish momentum and projected to range from $64.16 to $69.78 over the next five days.

Ongoing trial disclosures sustain selling despite research highlights

Monopar Therapeutics announced plans to present at AASLD - The Liver Meeting 2026, highlighting ongoing clinical progress through new Phase 3 FoCus baseline data and ALXN1840 molybdenum safety results. These updates reflect continued research activities in liver-related therapies, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views Monopar Therapeutics as firmly locked in a bearish cycle. He highlights the persistent failure to reclaim any key moving averages and the dominance of sellers, even after clinical news. Kharitonov is critical of intraday action, noting minimal volatility and an unconvincing response to research updates. He adds that technical indicators reinforce downside risks, while the price drifting near session lows signals continued negative sentiment. "Until Monopar breaks above $69.18 with conviction, I see little reason for optimism and expect further declines to test support at $64.16."

Viktoras Karapetjanc, expert at Traders Union, sees opportunity amid the current weakness. He believes Monopar's consistent clinical developments and upcoming baseline data presentation signal ongoing commitment and future value drivers. Karapetjanc remains constructive on the stock’s underlying potential, arguing that continued research activity could set the stage for renewed interest. He stresses that buyers may find attractive setups if the price holds above the $64.16 support. "Despite the present selloff, I expect Monopar’s pipeline news to eventually reignite bullish momentum and offer fresh growth opportunities going forward."

Jainam Mehta, market strategist, observes Monopar firmly positioned in a bearish zone while technical momentum remains negative. He notes that the current tight volatility band suggests a possible tactical play for range trading. Mehta points to mixed oscillator signals as an early sign of potential sentiment divergence, hinting at a contrarian entry if oversold extremes trigger a bounce. "I would closely watch for signs of reversal near $64.16, as any deviation from current weakness could present a short-term tactical trade."

Bearish structure prevails as technical signals reinforce downside risk

Monopar Therapeutics is trading below its 20-day, 50-day, and 200-day moving averages ($74.41, $91.1042, and $77.2402), confirming a sustained bearish structure across short-, medium-, and long-term trends. Near-term resistance is in place at $69.18, with support at $64.16, and the Ichimoku Kijun ($78.44) positioned well above current levels, reinforcing prevailing downward momentum. Momentum signals are decisively negative, with the Moving Average Convergence Divergence (MACD) forecasting “Strong Sell” and the Average Directional Index (ADX) indicating clear downside. The Relative Strength Index (RSI) suggests the stock is trending toward oversold levels, accompanied by a bearish reading from the Commodity Channel Index (CCI). Bull/Bear Power (BBP) is negative, signalling sellers currently dominate intraday momentum, and the “Oversold” assessment highlights persistent selling pressure. The stock last traded at $66.97, a decline of $3.71 or 5.25% for the session, following a clear downside gap of about $0.68 (0.96%) at the open. Price is near the day’s low, with minimal intraday volatility at 0.30%, reflecting persistent pressure after the open. The Stochastic RSI and Awesome Oscillator readings are neutral, indicating some divergence, but overall momentum aligns with the intraday weakness.

Earlier, analysts noted that Monopar Therapeutics was consolidating under persistent downside pressure amid unresolved technical uncertainty. The current analysis not only reinforces this bearish outlook with stronger negative momentum signals but also highlights the importance of closely monitoring the $64.16 support level for potential further downside in the days ahead.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.